Emmaus Life Sciences granted patent in India for use of PGLG
Emmaus Life Sciences announced the allowance by the Indian Patent Office of its patent application for methods and compositions of pharmaceutical-grade L-glutamine for the treatment of diverticulosis. The allowance of this application follows the issuance of corresponding patents in the United States, Europe, Japan, Australia, Mexico, China, Indonesia, South Korea and Russia. Patent applications are currently pending in various jurisdictions around the world, including Brazil. The allowed Indian patent application reports a significant reduction in the number of intestinal diverticula, the primary indicator of diverticulosis, through the therapeutic application of PGLG. The covered invention is directed to methods and compositions for the treatment of diverticulosis. More specifically this patent is directed to compositions including PGLG or uses of such compositions in the treatment of diverticulosis. Diverticulosis refers to a condition where small pouches form along the colon wall of the digestive tract. Over time, these pouches can often become inflamed and infected. Emmaus announced the initiation of the company's Pilot/Phase 1 clinical study of the treatment of diverticulosis with PGLG on July 8, 2019.